AC Immune Announces Upcoming Industry Symposium on Parkinson's Disease and Presentation at AD/PD™ 2026

AC Immune to host symposium highlighting Precision Prevention approach to Parkinson's disease
Presentation at International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2026) showcases potential of first-in-class TDP-43 PET-tracer ACI-19626

Lausanne, Switzerland, March 5, 2026 -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will host an industry symposium on how a precision prevention approach to Parkinson's disease may now be within reach, based on lessons from Alzheimer's disease.

AC Immune will also present its first-in-class TDP-43 PET-tracer on ACI-19626 at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2026) taking place in Copenhagen, Denmark, on March 17-21, 2026.

Industry Symposium: From Treatment to Prevention in Parkinson's Disease

Session Date/Time: Wednesday, March 18, 2026, 8:40 – 10:40 am CET

Location: Hall A1

Opening and Closing Remarks: Andrea Pfeifer, Ph.D., CEO of AC Immune
Shifting treatment to prevention: lessons learned from Alzheimer's disease

Presenter: Prof. Catherine Mummery (University College London)

Time: 8:45 – 9:00 am CET

Targeting α-synuclein in Parkinson's disease: pathophysiology and supporting evidence

Presenter: Werner Poewe, M.D. (Medical University of Innsbruck)

Time: 9:00 – 9:25 am CET

Misfolding of α-synuclein as fluid biomarker measured with the iRS platform of betaSENSE

Presenter: Prof. Klaus Gerwert (Centre for Protein Diagnostics at Ruhr University Bochum)

Time: 9:25 – 9:40 am CET

Stabilizing the progression of Parkinson's disease with active immunotherapy: Interim results of the Phase 2 VacSYn trial of ACI-7104.056

Presenter: Günther Staffler, Ph.D. (AC Immune)

Time: 9:40 – 10:05 am CET

Intracellular targeting of α-synuclein with Morphomer small molecules

Presenter: Francesca Capotosti, Ph.D. (AC Immune)

Time: 10:05 – 10:20 am CET

The presentations will be followed by a Q&A session, and a replay of the Industry Symposium will be available on the Events page of AC Immune's website after the event.

Oral Presentation

Discovery and initial clinical evaluation of [18f]ACI-19626, a first-in-class TDP-43 PET-tracer

Presenter: Tamara Seredenina, Ph.D. (AC Immune)

Session: Biomarker Pathways Linking Amyloid, Tau, and Neurodegeneration

Location: Hall 180-181

Date/Time: Thursday, March 19, 2026 at 4:50 – 5:05 pm CET

About AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CA, CN, CH, EU, GB, JP, KR, NO, RU and SG.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

For further information, please contact:

SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com
International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com

Forward looking statements

This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information – Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Attachment

20260305_ACIU ADPD Curtain raiser_FINAL